Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John G Kuhn

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 9, 2002
Chemotherapy-associated hematopoietic toxicityJohn G Kuhn
Oncology (Williston Park, N.Y.)|August 30, 2002
Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary reportJohn G Kuhn
The Oncologist|October 8, 2008
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategiesThomas E Hutson, Robert A Figlin, John G Kuhn, et al.
The American Journal of Emergency Medicine|December 18, 2007
Does intraosseous equal intravenous? A pharmacokinetic studyDaniel D Von Hoff, John G Kuhn, Howard A Burris, et al.
Investigational New Drugs|October 28, 2003
Positron emission tomography (PET): expanding the horizons of oncology drug developmentLisa A Hammond, Louis Denis, Umber Salman, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancerLeticia B A Rangel, Jodi L Taraba, Christopher R Frei, et al.
Molecular Pharmaceutics|February 28, 2018
Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica CastsZachary N Warnken, Hugh D C Smyth, Daniel A Davis, et al.
Pediatric Blood & Cancer|July 5, 2007
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group studyAnne-Marie Langevin, Mark Bernstein, John G Kuhn, et al.
Journal of Natural Products|January 24, 2017
Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJApril L Risinger, Jing Li, Lin Du, et al.
Journal of Pediatric Hematology/Oncology|July 9, 2003
Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group studyAnne-Marie Langevin, Steven D Weitman, John G Kuhn, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 9, 2002
Chemotherapy-associated hematopoietic toxicityJohn G Kuhn
Oncology (Williston Park, N.Y.)|August 30, 2002
Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary reportJohn G Kuhn
The Oncologist|October 8, 2008
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategiesThomas E Hutson, Robert A Figlin, John G Kuhn, et al.
The American Journal of Emergency Medicine|December 18, 2007
Does intraosseous equal intravenous? A pharmacokinetic studyDaniel D Von Hoff, John G Kuhn, Howard A Burris, et al.
Investigational New Drugs|October 28, 2003
Positron emission tomography (PET): expanding the horizons of oncology drug developmentLisa A Hammond, Louis Denis, Umber Salman, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancerLeticia B A Rangel, Jodi L Taraba, Christopher R Frei, et al.
Molecular Pharmaceutics|February 28, 2018
Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica CastsZachary N Warnken, Hugh D C Smyth, Daniel A Davis, et al.
Pediatric Blood & Cancer|July 5, 2007
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group studyAnne-Marie Langevin, Mark Bernstein, John G Kuhn, et al.
Journal of Natural Products|January 24, 2017
Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJApril L Risinger, Jing Li, Lin Du, et al.
Journal of Pediatric Hematology/Oncology|July 9, 2003
Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group studyAnne-Marie Langevin, Steven D Weitman, John G Kuhn, et al.
Pageof 5